HOME >> MEDICINE >> NEWS
Maxim Phase II Clinical Trial Highlights Substantial Increase In Leukemia-FreeSurvival For Acute Myelogenous Leukemia Patients

diseases and cancer, the capacity of the patient's immune system to detect and destroy diseased cells is compromised. Maxamine Therapy combines the administration of Maxamine, which protects critical immune cells, with the administration of cytokines such as interferons or IL-2, which stimulate these immune cells.

Maxim scientists have shown that the suppressive effect of the phagocytes, a class of white blood cells, is an important mechanism that prevents the immune system from effectively fighting cancer. Phagocytes release free-radicals that induce T-cells and NK-cells, immune cells that are critical in the fight against cancer and infectious diseases, into programmed cell death or apoptosis. Cytokines, such as IL-2 and interferon-a and vaccines are potent stimulators of T-cells and NK-cells, yet they are often rendered ineffective as therapeutics due to phagocyte-derived free-radical induction of programmed cell death of the critical immune cells. Maxamine has been shown to clearly and effectively prevent the production and release of phagocyte-derived free radicals, thereby protecting T-cells and NK-cells and enhancing the immune stimulating capabilities of certain cytokines and other immunotherapies.

Complementing the AML results described above, Phase II clinical studies of Maxamine Therapy in advanced malignant melanoma have shown a more than doubling in survival outcomes and the maintenance of patient quality of life during treatment. Earlier-stage clinical studies have also suggested promise in renal cell carcinoma and hepatitis. "The growing body of human data in several cancers and viral infections is leading Maxim into a clinical development program that focuses Maxamine as an immuno-modulator that may be used broadly to improve cytokine therapy, cancer vaccines and other stimulators of the immune system," stated Larry Stambaugh, chairman and chief executive officer of Maxim.

Maxim Pharmaceuticals, Inc.

Maxim Pharmaceuticals
'"/>

Contact: Amy Flood
a.flood@noonanrusso.com
415-677-4455 x211
Noonan/Russo Communications
7-Dec-1998


Page: 1 2 3 4 5 6

Related medicine news :

1. Elan and Biogen Idec announce results from Phase III maintenance trial of Antegren
2. Phase II trial of anthrax vaccine to begin
3. NIAID Phase III HIV vaccine trial to determine correlates of protection will not proceed
4. MetaPhore Pharmaceuticals initiates Phase I clinical trial of enzyme mimetic compound for oncology
5. Maret Pharmaceuticals presents promising Phase I/II clinical MARstem™ results at international symposium on new drugs in cancer therapy
6. Penn researchers announce results of Phase I trial using combretastatin drug
7. Anti-cocaine vaccine produces antibodies and is shown to be safe in Phase 1 study conducted by Yale researcher
8. Results of NUVANCE (IL-4 receptor) in Phase I/II study in asthma patients featured at AAAAI Late-Breaker Abstract and Asthma Therapy Sessions
9. ILEX Oncology & LeukoSite report results from pivotal Phase II CAMPATH (R) trial; Results suggest new hope for refractory chronic lymphocytic leukemia
10. Abgenix Reports Positive Survival Data From A Phase II Trial Of ABX-CBL In Graft Versus Host Disease
11. Immunex Advances CD40 Ligand To Phase II Clinical Trial In People With Metastatic Kidney Cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/19/2019)... ... 19, 2019 , ... NCPDP announced today that Dave deBronkart, ... will deliver the luncheon keynote on Tuesday, May 7, at its 2019 ... empowering partnerships between patients and their medical providers to NCPDP’s Annual Conference, May ...
(Date:2/19/2019)... ... , ... According to a recent study by Columbia University, more than 40% ... and only 26% of widows return to their pre-loss level of life satisfaction, according ... of the most tragic events that one can face. Consequently, many look for a ...
(Date:2/19/2019)... ... February 18, 2019 , ... AdventHealth Connerton is ... Solutions Footwear Sanitizing Stations to maximize infection control for patients and their families. ... as MRSA and C. difficile, which can be transmitted from the bottoms of ...
(Date:2/19/2019)... ... February 19, 2019 , ... ... Create Health, Wealth and Have the Life You Want!” (published by Balboa Press), ... with weight issues to release the pounds, reconnect to their dreams and attain ...
(Date:2/19/2019)... ... February 19, 2019 , ... STAR Institute for ... for occupational therapists beginning March 2019. The focus of the new program is to ... cases. The new Group Supervision Programs will be held on Zoom for five weekly ...
Breaking Medicine News(10 mins):
(Date:2/19/2019)... ... ... ExceleraRx Corporation announced today that St. Luke’s Health System has joined the ... the state of Idaho. , “We are very pleased to welcome St. ... Corp. “We believe St. Luke’s commitment to expanding and leveraging its pharmacy capabilities to ...
(Date:2/19/2019)... ... , ... The Jean Griswold Foundation, a nonprofit named for the founder of ... lives of seniors and others in the communities in which Griswold Home Care operates. ... couldn’t afford them. , “Each of these organizations have made such an ...
(Date:2/19/2019)... , ... February 19, 2019 , ... ... Florida, has completed his new book “Live Hard Die Young.” Dr. Oexner was ... practices chiropractic medicine, therapeutic exercise physiology, and nutritional counseling. Dr. Oexner was a ...
Breaking Medicine Technology:
Cached News: